Pneumococcal Polysaccarides and Nontypeable Haemophilus Influenzae (Nthi) Protein D Conjugate Vaccine (Phid-Cv): Synflorix

Pneumococcal disease is a leading cause of serious illness in children and the global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently, a new 10-valent pneumococcal nontypeable Haemophilus influenzae (NTHi) protein D (PD) conjugate vaccine (PHiD-CV, Synflorix ) has been licensed in more than 40 countries, including Europe, for the prevention of invasive disease and acute otitis media (AOM) due to pneumococcus in infants and children. PHiD-CV is immunogenic in infants when administered as a three-dose primary vaccination in a range of schedules and has a safety profile comparable to that of 7vCRM. Additional serotypes in PHiD-CV (1,5 and 7F) increase overall serotype coverage and improve coverage in specific age groups and against specific disease syndromes.